Publications
Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer’s disease.
Snellman A, Ekblad LL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Pietilä E, Koivumäki M, Helin S, Karrasch M, Zetterberg H, Blennow K, Rinne JO. Neurobiol Dis. 2023 Jul;183:106175. doi: 10.1016/j.nbd.2023.106175. Epub 2023 Jun 1.
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease.
Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER,...
Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.
De Bastiani MA, Bellaver B, Brum WS, Souza DG, Ferreira PCL, Rocha AS, Povala G, Ferrari-Souza JP, Benedet AL, Ashton NJ, Karikari TK, Zetterberg H, Blennow K, Rosa-Neto P, Pascoal TA, Zimmer ER; Alzheimer's Disease Neuroimaging Initiative. Brain Behav Immun. 2023...
Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
Ashton NJ, Puig-Pijoan A, Milà-Alomà M, Fernández-Lebrero A, García-Escobar G, González-Ortiz F, Kac PR, Brum WS, Benedet AL, Lantero-Rodriguez J, Day TA, Vanbrabant J, Stoops E, Vanmechelen E, Triana-Baltzer G, Moughadam S, Kolb H, Ortiz-Romero P, Karikari TK,...
Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations.
Brown J, Camporesi E, Lantero-Rodriguez J, Olsson M, Wang A, Medem B, Zetterberg H, Blennow K, Karikari TK, Wall M, Hill E. Acta Neuropathol Commun. 2023 Apr 24;11(1):67. doi: 10.1186/s40478-023-01562-5.
Longitudinal changes in Alzheimer’s-related plasma biomarkers and brain amyloid.
Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Jedynak BM, Thambisetty M, Ferrucci L, Resnick SM. medRxiv [Preprint]. 2023 Apr 21:2023.01.12.23284439. doi: 10.1101/2023.01.12.23284439.
APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles.
Ferrari-Souza JP, Lussier FZ, Leffa DT, Therriault J, Tissot C, Bellaver B, Ferreira PCL, Malpetti M, Wang YT, Povala G, Benedet AL, Ashton NJ, Chamoun M, Servaes S, Bezgin G, Kang MS, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, O'Brien JT, Rowe JB, Cohen AD,...
APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
Snellman A, Ekblad LL, Tuisku J, Koivumäki M, Ashton NJ, Lantero-Rodriguez J, Karikari TK, Helin S, Bucci M, Löyttyniemi E, Parkkola R, Karrasch M, Schöll M, Zetterberg H, Blennow K, Rinne JO. Alzheimers Res Ther. 2023 Apr 4;15(1):71. doi:...
Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study.
Montoliu-Gaya L, Alcolea D, Ashton NJ, Pegueroles J, Levin J, Bosch B, Lantero-Rodriguez J, Carmona-Iragui M, Wagemann O, Balasa M, Kac PR, Barroeta I, Lladó A, Brum WS, Videla L, Gonzalez-Ortiz F, Benejam B, Arranz Martínez JJ, Karikari TK, Nübling G, Bejanin A,...
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest.
Ashton NJ, Moseby-Knappe M, Benedet AL, Grötschel L, Lantero-Rodriguez J, Karikari TK, Hassager C, Wise MP, Stammet P, Kjaergaard J, Friberg H, Nielsen N, Cronberg T, Zetterberg H, Blennow K. JAMA Neurol. 2023 Apr 1;80(4):388-396. doi: 10.1001/jamaneurol.2023.0050.
Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease.
Chong JR, Hilal S, Ashton NJ, Karikari TK, Reilhac A, Vrooman H, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP. Alzheimers Dement (Amst). 2023 Mar 26;15(1):e12396. doi: 10.1002/dad2.12396. eCollection 2023 Jan-Mar.
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications.
Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Mol Neurodegener. 2023 Mar 16;18(1):18. doi: 10.1186/s13024-023-00605-8.
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
Lantero-Rodriguez J, Vrillon A, Fernández-Lebrero A, Ortiz-Romero P, Snellman A, Montoliu-Gaya L, Brum WS, Cognat E, Dumurgier J, Puig-Pijoan A, Navalpotro-Gómez I, García-Escobar G, Karikari TK, Vanmechelen E, Ashton NJ, Zetterberg H, Suárez-Calvet M, Paquet C,...
Blood-brain barrier opening of the default mode network in Alzheimer’s disease with magnetic resonance-guided focused ultrasound.
Meng Y, Goubran M, Rabin JS, McSweeney M, Ottoy J, Pople CB, Huang Y, Storace A, Ozzoude M, Bethune A, Lam B, Swardfager W, Heyn C, Abrahao A, Davidson B, Hamani C, Aubert I, Zetterberg H, Ashton NJ, Karikari TK, Blennow K, Black SE, Hynynen K, Lipsman N. Brain. 2023...
Plasma biomarkers for neurodegenerative disorders: ready for prime time?
Balogun WG, Zetterberg H, Blennow K, Karikari TK. Curr Opin Psychiatry. 2023 Mar 1;36(2):112-118. doi: 10.1097/YCO.0000000000000851. Epub 2023 Jan 16.
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration.
Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, Benussi L, Cantoni V, Saraceno C, Rivolta J, Ashton NJ, Borroni B, Galasko D, Harrison P, Zetterberg H, Blennow K, Karikari TK. Brain. 2023 Mar 1;146(3):1152-1165. doi: 10.1093/brain/awac407.
Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults.
Leffa DT, Ferrari-Souza JP, Bellaver B, Tissot C, Ferreira PCL, Brum WS, Caye A, Lord J, Proitsi P, Martins-Silva T, Tovo-Rodrigues L, Tudorascu DL, Villemagne VL, Cohen AD, Lopez OL, Klunk WE, Karikari TK, Rosa-Neto P, Zimmer ER, Molina BSG, Rohde LA, Pascoal TA;...
Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease.
Pascoal T, Bellaver B, Povala G, Ferreira P, Ferrari-Souza JP, Leffa D, Lussier F, Benedet A, Ashton N, Triana-Baltzerz G, Kolbzh H, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez O, Tudorascu D, Villemagne V, Ikonomovic M, Gauthier S, Zimmer E,...
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, Fernandez-Arias J, Socualaya KQ, Macedo AC, Ferrari-Souza JP, Ferreira PCL, Bellaver B,...
A Validated Method to Prepare Stable Tau Oligomers.
Hill E, Moffat KG, Wall MJ, Zetterberg H, Blennow K, Karikari TK. Methods Mol Biol. 2023;2551:203-224. doi: 10.1007/978-1-0716-2597-2_14.
Functional Applications of Stable Tau Oligomers in Cell Biology and Electrophysiology Studies.
Hill E, Moffat KG, Wall MJ, Zetterberg H, Blennow K, Karikari TK. Methods Mol Biol. 2023;2551:147-161. doi: 10.1007/978-1-0716-2597-2_11.
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
Simrén J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, Sjons E, Lussier FZ, Chamoun M, Stevenson J, Hopewell R, Pallen V, Ye K, Pascoal TA, Zetterberg H, Rosa-Neto P, Blennow K. Alzheimers Res Ther. 2022 Dec 22;14(1):192. doi:...
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.
Gobom J, Benedet AL, Mattsson-Carlgren N, Montoliu-Gaya L, Schultz N, Ashton NJ, Janelidze S, Servaes S, Sauer M, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brinkmalm G, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K. Mol Neurodegener. 2022 Dec 12;17(1):81. doi:...
CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.
Moscoso A, Karikari TK, Grothe MJ, Ashton NJ, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M. Alzheimers Dement. 2022 Dec;18(12):2614-2626. doi: 10.1002/alz.12570. Epub 2022 Feb 28.
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.
Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, González-Ortiz F, Di Molfetta G, Meda FJ, Jonaitis EM, Koscik RL, Cody K, Betthauser TJ, Li Y, Vanmechelen E, Palmqvist S, Stomrud E, Bateman RJ, Zetterberg H, Johnson SC,...
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease.
Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, Brum WS, Benedet AL, Ashton NJ, De Bastiani MA, Rocha A, Therriault J, Lussier FZ, Chamoun M, Servaes S, Bezgin G, Kang MS, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Klunk WE, Tudorascu...
Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer’s disease neuropathology and regional tau at autopsy.
Morrison MS, Aparicio HJ, Blennow K, Zetterberg H, Ashton NJ, Karikari TK, Tripodis Y, Martin B, Palmisano JN, Sugarman MA, Frank B, Steinberg EG, Turk KW, Budson AE, Au R, Goldstein LE, Jun GR, Kowall NW, Killiany R, Qiu WQ, Stern RA, Mez J, McKee AC, Stein TD,...